{"id":2755,"date":"2017-08-12T11:10:18","date_gmt":"2017-08-12T11:10:18","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/2017\/08\/12\/kliiniline-ja-translatsiooniline-onkoloogia-sugava-hupertermia-ja-kiiritusravi-programmi-teostatavus-kaugelearenenud-kasvajate-puhul-esimene-hispaania-kogemus\/"},"modified":"2025-09-02T13:35:31","modified_gmt":"2025-09-02T13:35:31","slug":"kliiniline-uuring-hupertermia","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/et\/kliiniline-uuring-hupertermia\/","title":{"rendered":"Kliiniline uuring: Keemiaravi koos h\u00fcpertermia ja suure annusega brahh\u00fcteraapia esialgsed tulemused lokaalselt levinud emakakaelav\u00e4hi ravis ESHO"},"content":{"rendered":"<div><\/div>\n<div class=\"clinical_trial\">\n<h1 style=\"text-align: center;\"><a href=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/POSTER-HT-ESHO-2014-clarke.pdf\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kliiniline uuring: Keemiaravi koos h\u00fcpertermia ja suure annusega brahh\u00fcteraapia esialgsed tulemused lokaalselt levinud emakakaelav\u00e4hi ravis<\/span><\/span><\/a><\/h1>\n<h2 style=\"text-align: center;\"><a href=\"https:\/\/www.esho.info\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Andromedic h\u00fcpertermia kliiniline uuring &#8211; Euroopa H\u00fcpertermilise Onkoloogia Seltsi kongress 2014\u00a0<\/span><\/span><\/a><\/h2>\n<h2 style=\"text-align: center;\"><\/h2>\n<figure id=\"attachment_114\" aria-describedby=\"caption-attachment-114\" style=\"width: 590px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-114 size-full\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma.jpg\" alt=\"Kliiniline uuring - Keemiaravi ja kiiritusravi koos andromeedilise h\u00fcpertermia ja suure annusega brahh\u00fcteraapia esialgsed tulemused lokaalselt levinud emakakaelav\u00e4hi ravis\" width=\"590\" height=\"837\" title=\"\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma.jpg 590w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Preliminary-results-of-chemoradiation-plus-hyperthermia-and-high-dose-rate-brachytherapy-for-locally-advanced-cervical-carcinoma-211x300.jpg 211w\" sizes=\"auto, (max-width: 590px) 100vw, 590px\" \/><figcaption id=\"caption-attachment-114\" class=\"wp-caption-text\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Lokaalselt levinud emakakaelav\u00e4hi keemiaravi ja kiiritusravi koos andromeedilise h\u00fcpertermia ja suure annusega brahh\u00fcteraapia esialgsed tulemused<\/span><\/span><\/figcaption><\/figure>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">E. Clarke, V. De Sanctis, C. Scaringi, M. Valeriani, MF Osti, R. Maurizi Enrici Sant&#8217;Andrea haigla, kiiritusravi osakond, Rooma Sapienza \u00fclikool, Rooma, Itaalia<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EESM\u00c4RGID<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Uurida keemiaravi koos h\u00fcpertermiaga (HT) ja suure annusega brahh\u00fcteraapiaga (BRT) ravi tulemusi lokaalselt levinud emakakaelav\u00e4hi (LACC) korral. Kas keemiaravi koos kiiritusraviga peetakse LACC standardraviks. HT lisamine ainult kiiritusravile (RT) on n\u00e4idanud, et see parandab lokaalset kasvaja kontrolli ja \u00fcldist elulemust, m\u00f5jutamata raviga seotud 3. kuni 4. astme \u00e4gedat v\u00f5i hilist toksilisust selles patsientide r\u00fchmas.<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">MATERJALID JA MEETODID<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Jaanuarist 2013 kuni detsembrini 2013 osales pilootuuringus 8 LACC-ga ehk lokaalselt retsidiveerunud emakakaelav\u00e4higa (LRCC) patsienti p\u00e4rast h\u00fcsterektoomiat (vastavalt 3 staadiumi IIB, I IIIB, 2 NEI ja 3 LRCC). Uuringus kombineeriti igan\u00e4dalast tsisplatiini ja HT-d intensiivsusmoduleeritud kiiritusraviga (IMRT), millele j\u00e4rgnes BRT. 5,5 n\u00e4dala jooksul manustati vaagna l\u00fcmfis\u00f5lmedesse 50,4 Gy annus koos samaaegse integreeritud v\u00f5imendusega (SIB) kasvaja kogumahule (GTV) kokku 61,8 Gy-ni 28 fraktsioonina. BRT annus oli 21 Gy 3 fraktsioonina. Samaaegne keemiaravi raviskeem koosnes igan\u00e4dalasest tsisplatiinist annuses 4 mg\/m2 ja HT-st \u00fcks kord n\u00e4dalas.<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">TULEMUSED K\u00f5ik patsiendid saavutasid lokaalse kontrolli. \u00dchel patsiendil tekkis retsidiiv v\u00e4ljaspool vaagnat, millega kaasnes mitmete luude ja paraaortaalsete l\u00fcmfis\u00f5lmede haaratus. Raviga seotud \u00e4gedat ega hilist 3. kuni 4. astme toksilisust ei t\u00e4heldatud.<\/span><\/span><\/strong><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">J\u00c4RELDUSED See raviskeem oli h\u00e4sti talutav ja andis hea kliinilise vastuse. HT lisamine keemiaravile ja kiiritusravile kujutab endast paljulubavat uut strateegiat.<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Selle efektiivsuse kinnitamiseks on vaja mitme asutuse koost\u00f6\u00f6d ja pikemat j\u00e4lgimisperioodi.<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">BIBLIOGRAAFIA<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. Lutgens L. van der Zee J. Pijls-Johannesma M, De Haas-Kock DF, Buijsen J. Mastrigt GA. Lammering G. De Ruysscher DK. Lambin R. H\u00fcpertermia ja kiiritusravi kombineeritud kasutamine lokaalselt levinud emakakaelav\u00e4hi ravis. Cochrane Database Syst Rev. 2010 m\u00e4rts 17:(3):CD008377. doi:10.1002\/14851858.CD006377.pub3.<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. van der Zee J. Gonzalez Gonzalez D. van Rhoon GC, van Dijk JD. van Pullen WL, Hart AA. Ainult kiiritusravi ja kiiritusravi koos h\u00fcpertermiaga v\u00f5rdlus lokaalselt levinud vaagna kasvajate korral: prospektiivne, randomiseeritud, mitmekeskuseline uuring. Hollandi Deep Hyperthemba Group. Lancet. 1. aprill 2000:355(9210):1119-25.<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Green J, Kirwan 0,1, Tremey J. Vale C. Symonds R. Fresco L. Williams C. Collingwood M. Emakakaela v\u00e4hi samaaegne keemiaravi ja kiiritusravi. Cochrane Database Syst Rev. 20. juuli 2005;(3):C0002225.<\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Kliiniline uuring: Keemiaravi koos h\u00fcpertermia ja suure annusega brahh\u00fcteraapia esialgsed tulemused lokaalselt levinud emakakaelav\u00e4hi ravis Andromedic h\u00fcpertermia kliiniline uuring &#8211; Euroopa H\u00fcpertermilise Onkoloogia Seltsi kongress 2014\u00a0 E. Clarke, V. De Sanctis, C. Scaringi, M. Valeriani, MF Osti, R. Maurizi Enrici Sant&#8217;Andrea haigla, kiiritusravi osakond, Rooma Sapienza \u00fclikool, Rooma, Itaalia EESM\u00c4RGID Uurida keemiaravi koos h\u00fcpertermiaga (HT)&hellip;<\/p>\n","protected":false},"author":1,"featured_media":7015,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[108],"tags":[132,131,130,134,133],"class_list":["post-2755","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uudised","tag-hupertermia","tag-kaugelearenenud-kasvajad","tag-kiiritusravi","tag-kohalik-hupertermia","tag-meht-et"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/posts\/2755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/comments?post=2755"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/posts\/2755\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/media\/7015"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/media?parent=2755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/categories?post=2755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/tags?post=2755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}